+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PARP Inhibitors Drug Therapy Market by Indication, Drug, Line of Therapy, Treatment Setting, End User, Distribution Channel, Therapy Type, Patient Age Group - Global Forecast to 2030- Product Image
PARP Inhibitors Drug Therapy Market by Indication, Drug, Line of Therapy, Treatment Setting, End User, Distribution Channel, Therapy Type, Patient Age Group - Global Forecast to 2030- Product Image
Sale

PARP Inhibitors Drug Therapy Market by Indication, Drug, Line of Therapy, Treatment Setting, End User, Distribution Channel, Therapy Type, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674431
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior leaders navigating the oncology sector now face unprecedented complexity as PARP inhibitors reshape cancer therapy, regulatory frameworks evolve, and dynamic market drivers redefine commercial strategies. This comprehensive report provides actionable intelligence for forward-thinking decision-makers tasked with optimizing both patient outcomes and organizational performance.

Market Snapshot: Growth and Opportunity in PARP Inhibitors Drug Therapy

The PARP Inhibitors Drug Therapy Market grew from USD 7.32 billion in 2024 to USD 8.01 billion in 2025. It is expected to continue growing at a CAGR of 9.24%, reaching USD 12.44 billion by 2030. This strong trajectory is fueled by expanding therapeutic applications, regulatory momentum, and evolving evidence supporting use across breast, ovarian, pancreatic, and prostate oncology indications. Layered segmentation, robust regional dynamics, and competitive product innovation are transforming precision oncology and redefining payer-provider partnerships.

Scope & Segmentation

This report delves into the granular drivers of growth and adoption, providing in-depth coverage across clinical, technological, and geographic dimensions. Segmentation supports targeted strategy development and efficient resource allocation for stakeholders across the pharmaceutical and healthcare landscape.

  • Indication: Insight into breast cancer (hormone receptor-positive, triple negative), ovarian cancer (biomarker status: BRCA-mutated, HRD, Non-HRD), pancreatic cancer (advanced, early stage), prostate cancer (metastatic, non-metastatic).
  • Drug: Comprehensive analysis of Niraparib, Olaparib, Rucaparib, Talazoparib.
  • Line Of Therapy: Examination of first-line, maintenance, and subsequent-line use cases.
  • Treatment Setting: Review of inpatient and outpatient care models.
  • End User: Profiling of hospitals, retail pharmacies, and specialty clinics.
  • Distribution Channel: Mapping of hospital pharmacies, online pharmacies, and retail pharmacies.
  • Therapy Type: Analysis of combination therapy versus monotherapy adoption.
  • Patient Age Group: Focus on adults and elderly populations.
  • Geographies: Coverage spans major regional markets, including the Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (featuring key countries such as UK, Germany, France, UAE, South Africa), and Asia-Pacific (China, India, Japan, Australia, and more).
  • Key Players: In-depth profiles of AstraZeneca plc, GlaxoSmithKline plc, Clovis Oncology, Inc., Pfizer Inc., Merck & Co., Inc.

Key Takeaways

  • PARP inhibitors have shifted from niche use to a foundational element in advanced oncology care, influencing treatment protocols and driving the adoption of precision medicine.
  • Drug performance and patient outcomes are increasingly shaped by advancements in molecular diagnostics and real-world evidence, supporting tailored regimens and refined patient stratification.
  • Strategic alliances, including partnerships between multinational and regional distributors, are accelerating commercialization and optimizing market access in both established and emerging markets.
  • Combination regimens and novel delivery platforms offer avenues for differentiation among branded competitors, reinforcing the importance of continuous clinical development.
  • Regulatory and payer variation across regions necessitates agile market access models and custom engagement strategies to ensure widespread availability and sustainable growth.
  • End-to-end supply chain efficiency and digital engagement tools are proving critical in streamlining therapy management and expanding disease awareness among healthcare professionals.

Tariff Impact: Navigating US Revisions and Access Strategies

US tariff adjustments slated for 2025 will affect import costs for patented oncology medicines, including both active pharmaceutical ingredients and finished products. These revisions challenge global manufacturers to reassess supply chain and near-shoring solutions, while domestic producers evaluate cost and distribution reconfigurations. Industry groups and regulators are examining exemptions to alleviate immediate access constraints, but longer-term commercial models must account for additional overhead through pricing and strategic partnerships.

Methodology & Data Sources

Findings in this report originate from a multi-tiered approach, integrating comprehensive secondary research, structured primary interviews with oncologists, payers, and healthcare administrators, and robust data triangulation. Peer-reviewed studies, regulatory documents, and validated industry consortiums provide the evidence base, with further context drawn from patient advocacy group feedback to ensure real-world relevance.

Why This Report Matters

  • Supports data-driven commercial decisions by dissecting evolving clinical trends, payer requirements, and competitive landscapes within the global PARP inhibitor ecosystem.
  • Enables senior stakeholders to anticipate regulatory and supply chain challenges, ensuring readiness for policy shifts and emerging market disruptions.
  • Empowers strategic planning with up-to-date intelligence on combination therapies, regional engagement, and value-based market positioning.

Conclusion

PARP inhibitors continue to transform global oncology through innovation, strategic partnerships, and robust commercialization. Real-time insights into regulatory, clinical, and regional dynamics guide leadership teams in sustaining competitive advantage in a rapidly evolving market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. PARP Inhibitors Drug Therapy Market, by Indication
8.1. Introduction
8.2. Breast Cancer
8.2.1. Receptor Type
8.2.1.1. Hormone Receptor Positive
8.2.1.2. Triple Negative
8.3. Ovarian Cancer
8.3.1. Biomarker Status
8.3.1.1. Brca Mutated
8.3.1.2. Hrd
8.3.1.3. Non-Hrd
8.4. Pancreatic Cancer
8.4.1. Stage
8.4.1.1. Advanced
8.4.1.2. Early Stage
8.5. Prostate Cancer
8.5.1. Stage
8.5.1.1. Metastatic
8.5.1.2. Non-Metastatic
9. PARP Inhibitors Drug Therapy Market, by Drug
9.1. Introduction
9.2. Niraparib
9.3. Olaparib
9.4. Rucaparib
9.5. Talazoparib
10. PARP Inhibitors Drug Therapy Market, by Line of Therapy
10.1. Introduction
10.2. First Line
10.3. Maintenance
10.4. Subsequent Line
11. PARP Inhibitors Drug Therapy Market, by Treatment Setting
11.1. Introduction
11.2. Inpatient
11.3. Outpatient
12. PARP Inhibitors Drug Therapy Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Retail Pharmacies
12.4. Specialty Clinics
13. PARP Inhibitors Drug Therapy Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. PARP Inhibitors Drug Therapy Market, by Therapy Type
14.1. Introduction
14.2. Combination Therapy
14.3. Monotherapy
15. PARP Inhibitors Drug Therapy Market, by Patient Age Group
15.1. Introduction
15.2. Adults
15.3. Elderly
16. Americas PARP Inhibitors Drug Therapy Market
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. Argentina
17. Europe, Middle East & Africa PARP Inhibitors Drug Therapy Market
17.1. Introduction
17.2. United Kingdom
17.3. Germany
17.4. France
17.5. Russia
17.6. Italy
17.7. Spain
17.8. United Arab Emirates
17.9. Saudi Arabia
17.10. South Africa
17.11. Denmark
17.12. Netherlands
17.13. Qatar
17.14. Finland
17.15. Sweden
17.16. Nigeria
17.17. Egypt
17.18. Turkey
17.19. Israel
17.20. Norway
17.21. Poland
17.22. Switzerland
18. Asia-Pacific PARP Inhibitors Drug Therapy Market
18.1. Introduction
18.2. China
18.3. India
18.4. Japan
18.5. Australia
18.6. South Korea
18.7. Indonesia
18.8. Thailand
18.9. Philippines
18.10. Malaysia
18.11. Singapore
18.12. Vietnam
18.13. Taiwan
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. AstraZeneca plc
19.3.2. GlaxoSmithKline plc
19.3.3. Clovis Oncology, Inc.
19.3.4. Pfizer Inc.
19.3.5. Merck & Co., Inc.
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. PARP INHIBITORS DRUG THERAPY MARKET MULTI-CURRENCY
FIGURE 2. PARP INHIBITORS DRUG THERAPY MARKET MULTI-LANGUAGE
FIGURE 3. PARP INHIBITORS DRUG THERAPY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 22. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. PARP INHIBITORS DRUG THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. PARP INHIBITORS DRUG THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PARP INHIBITORS DRUG THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BRCA MUTATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HRD, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NON-HRD, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADVANCED, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY METASTATIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NON-METASTATIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBSEQUENT LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 92. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 94. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 95. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 96. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 97. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 98. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 99. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 100. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 101. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 102. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 103. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 104. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 107. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 108. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 109. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 110. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 111. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 112. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 113. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 114. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 115. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 116. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 117. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 118. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 119. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 120. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 123. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 174. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 176. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 178. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 180. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 182. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 189. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 190. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 191. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 192. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 193. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 194. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 195. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 196. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 197. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 198. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 199. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 200. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 201. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 204. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 205. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 206. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 207. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 208. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 209. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 210. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 211. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 212. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 213. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 214. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 215. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 216. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 217. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 220. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 221. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 222. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 223. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 224. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 225. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 226. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 227. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 237. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 238. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 239. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 240. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 241. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 242. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 243. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 244. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 245. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 246. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 247. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 248. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 249. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 252. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 253. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 254. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 255. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 256. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 257. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 258. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 259. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 260. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 261. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 262. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 263. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 264. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 265. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 268. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 285. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 286. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 287. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 288. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 289. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 290. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 291. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 292. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 293. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 294. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 296. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 300. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 301. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 302. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 303. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2030 (USD MILLION)
TABLE 304. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD MILLION)
TABLE 305. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2030 (USD MILLION)
TABLE 306. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD MILLION)
TABLE 307. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 308. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 309. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 310. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THER

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this PARP Inhibitors Drug Therapy market report include:
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Clovis Oncology, Inc.
  • Pfizer Inc.
  • Merck & Co., Inc.

Table Information

Report AttributeDetails
No. of Pages192
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 8.01 Billion
Forecasted Market Value ( USD ) by 2030 $ 12.44 Billion
Compound Annual Growth Rate9.2%
Regions CoveredGlobal
No. of Companies Mentioned6

Related Topics

Related Reports

Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report 2025 - Product Image

Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Report 2025 - Product Image

Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Report 2025

  • Report
  • 175 Pages
  • Global
From
PARP Inhibitor Biomarkers - Global Strategic Business Report - Product Image

PARP Inhibitor Biomarkers - Global Strategic Business Report

  • Report
  • 278 Pages
  • Global
From
PARP Inhibitor Biomarkers Market by Product, by Service 1 & 2 Testing, by Application, by End-User, and By Region - Product Image

PARP Inhibitor Biomarkers Market by Product, by Service 1 & 2 Testing, by Application, by End-User, and By Region

  • Report
  • 200 Pages
  • Global
From
PARP Inhibitor Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

PARP Inhibitor Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.